PTEN Antibody (B-1): sc-133197

PTEN Antibody (B-1) is a mouse monoclonal IgG2b kappa light chain antibody engineered to recognize the full-length PTEN protein, also known as phosphatase and tensin homolog, MMAC1, or TEP1. PTEN monoclonal antibody (B-1) targets amino acids 1-403 of human PTEN and is validated for use in western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA) applications across mouse, rat, and human species. PTEN is a pivotal tumor suppressor protein that plays a crucial role in regulating cell growth, proliferation, and survival by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate, thereby antagonizing the PI3K/AKT signaling pathway. The proper functioning of PTEN is essential for maintaining cellular homeostasis and preventing uncontrolled cell division, which is why loss or mutation is frequently associated with various cancers, including glioblastomas, breast, kidney, and prostate cancers. PTEN interacts with several key proteins, such as p53, which enhances tumor-suppressive functions, and PDZ domain-containing proteins like MAGI-2 and MAGI-3, which help regulate stability and localization within the cell. Additionally, PTEN forms complexes with proteins like AKT and SHC, modulating downstream signaling pathways that influence cell migration and apoptosis. Anti-PTEN antibody (B-1) enables researchers to effectively investigate these protein-protein interactions and elucidate the molecular mechanisms by which PTEN exerts tumor suppressor activities. PTEN (B-1) antibody serves as an invaluable tool for studies focused on cancer biology, enabling detailed analysis of PTEN-related pathways and the development of targeted therapeutic strategies aimed at restoring function in cancerous cells.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PTEN Antibody (B-1) References:

1. PTEN: its deregulation and tumorigenesis.  |  Maehama, T. 2007. Biol Pharm Bull. 30: 1624-7. PMID: 17827710
2. PTEN: a new guardian of the genome.  |  Yin, Y. and Shen, WH. 2008. Oncogene. 27: 5443-53. PMID: 18794879
3. PTEN in cancer, metabolism, and aging.  |  Ortega-Molina, A. and Serrano, M. 2013. Trends Endocrinol Metab. 24: 184-9. PMID: 23245767
4. PTEN plasticity: how the taming of a lethal gene can go too far.  |  Naguib, A. and Trotman, LC. 2013. Trends Cell Biol. 23: 374-9. PMID: 23578748
5. Study of PTEN subcellular localization.  |  Bononi, A. and Pinton, P. 2015. Methods. 77-78: 92-103. PMID: 25312582
6. Focus on PTEN Regulation.  |  Bermúdez Brito, M., et al. 2015. Front Oncol. 5: 166. PMID: 26284192
7. Reversible oxidation of phosphatase and tensin homolog (PTEN) alters its interactions with signaling and regulatory proteins.  |  Verrastro, I., et al. 2016. Free Radic Biol Med. 90: 24-34. PMID: 26561776
8. PTEN in the maintenance of genome integrity: From DNA replication to chromosome segregation.  |  Hou, SQ., et al. 2017. Bioessays. 39: PMID: 28891157
9. PTEN and Gynecological Cancers.  |  Nero, C., et al. 2019. Cancers (Basel). 11: PMID: 31569439
10. Approaches to Investigating the Protein Interactome of PTEN.  |  Smith, SL., et al. 2021. J Proteome Res. 20: 60-77. PMID: 33074689

The preferred PTEN antibody is PTEN Antibody (A2B1): sc-7974.